Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant
Edara, V.-V.; Lai, L.; Sahoo, M.; Floyd, K.; Sibai, M.; Solis, D.; Flowers, M. W.; Hussaini, L.; Ciric, C. R.; Bechnack, S.; Stephens, K.; Mokhtari, E. B.; Mudvari, P.; Creanga, A.; Pegu, A.; Derrien-Colemyn, A.; Henry, A. R.; Gagne, M.; Graham, B. S.; Wrammert, J.; Douek, D. C.; Bortiz, E.; Pinsky, B. A.; Suthar, M.
Show abstract
SARS-CoV-2 has caused a devastating global pandemic. The recent emergence of SARS-CoV-2 variants that are less sensitive to neutralization by convalescent sera or vaccine-induced neutralizing antibody responses has raised concerns. A second wave of SARS-CoV-2 infections in India is leading to the expansion of SARS-CoV-2 variants. The B.1.617.1 variant has rapidly spread throughout India and to several countries throughout the world. In this study, using a live virus assay, we describe the neutralizing antibody response to the B.1.617.1 variant in serum from infected and vaccinated individuals. We found that the B.1.617.1 variant is 6.8-fold more resistant to neutralization by sera from COVID-19 convalescent and Moderna and Pfizer vaccinated individuals. Despite this, a majority of the sera from convalescent individuals and all sera from vaccinated individuals were still able to neutralize the B.1.617.1 variant. This suggests that protective immunity by the mRNA vaccines tested here are likely retained against the B.1.617.1 variant. As the B.1.617.1 variant continues to evolve, it will be important to monitor how additional mutations within the spike impact antibody resistance, viral transmission and vaccine efficacy.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination 96%
- Structure selected RBM immunogens prime polyclonal memory responses that neutralize SARS-CoV-2 variants of concern 94%
- Contemporary HIV-1 envelope pseudovirus panels for detecting and assessing B cell lineages with broadly neutralizing antibody potential 94%
Similar papers in this journal
- SARS-CoV-2 evolution and patient immunological history shape the breadth and potency of antibody-mediated immunity 95%
- Virological and serological characterization of critically ill patients with COVID-19 in the UK: a special focus on variant detection 93%
- Serological reconstruction of COVID-19 epidemics through analysis of antibody kinetics to SARS-CoV-2 proteins 93%
Similar papers in this journal
Similar papers in this journal
- Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape over Time 96%
- Broad neutralization of SARS-CoV-2 variants, including omicron, following breakthrough infection with delta in COVID-19 vaccinated individuals 95%
- Low levels of H5N1 HA and NA antibodies in the human population are boosted by seasonal A/H1N1 infection but not by A/H3N2 infection or influenza vaccination 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.